Functional Ovarian Cysts in Artificial Frozen-Thawed Embryo Transfer Cycles With Depot Gonadotropin-Releasing Hormone Agonist

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 May 16

PMID 35574002

Authors

Hui Ji

Yan Su

Mianqiu Zhang

Xin Li

Xiuling Li

Hui Ding

Li Dong

Shanren Cao

Chun Zhao

Junqiang Zhang

Rong Shen

Xiufeng Ling

Affiliations

Soon will be listed here.

Abstract

Objectives: To investigate the incidence of functional ovarian cysts, its influence on clinical rates, and proper management after depot gonadotropin-releasing hormone (GnRH) agonist pretreatment in artificial frozen-thawed embryo transfer cycles (AC-FET).

Methods: This retrospective cohort study involved 3375 AC-FET cycles with follicular-phase depot GnRH agonist administration between January 2017 and December 2020. Subjects were divided into a study group (cycles with cyst formation) and a control group (cycles without cyst formation). The study group was matched by propensity scoring matching with the control group at a ratio of 1:2. For patients with ovarian cyst formation, two major managements were used: a conservative approach (i.e., expectant treatment) and a drug approach (i.e., continued agonist administration). The primary outcome was live birth rate (LBR).

Results: The incidence of functional ovarian cysts following pituitary downregulation is 10.1% (341/3375). The study group exhibited a LBR similar to the control group (54.5% . 50.1%, adjusted odds ratio [aOR] 1.17, 95% confidence interval [CI] 0.88-1.56, 0.274). Patients with a lower body mass index and anti-Müllerian hormone, and a higher basal estradiol level were more susceptible to developing functional ovarian cysts. The LBR decreased after the drug approach compared with the conservative approach, but not significantly (aOR 0.63, 95% CI 0.35-1.14, 0.125). Following the conservative approach, cycles arrived at live births had a significantly shorter duration from the detection of functional cysts to the start of endometrium preparation (15.7 ± 5.1 days . 17.4 ± 5.3 days, = 0.009) and a significantly higher proportion of ovarian cysts on the initial day of exogenous hormone supplementation (51.4% . 30.3%, = 0.001). After controlling for all confounders, the differences remained statistically significant.

Conclusions: It is unnecessary to cancel cycles that experience functional ovarian cyst formation. Conservative management and further agonist suppression protocol had similar pregnancy rates. However, a conservative approach was recommended due to its lower cost and fewer side effects. Our findings support a shorter waiting period when choosing the conservative protocol.

References

Patrelli T, Gizzo S, Sianesi N, Levati L, Pezzuto A, Ferrari B . Anti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles?. PLoS One. 2012; 7(9):e44571. PMC: 3439394. DOI: 10.1371/journal.pone.0044571. View

Yang X, Huang R, Wang Y, Liang X . Pituitary suppression before frozen embryo transfer is beneficial for patients suffering from idiopathic repeated implantation failure. J Huazhong Univ Sci Technolog Med Sci. 2016; 36(1):127-131. DOI: 10.1007/s11596-016-1554-2. View

Lan J, Wu Y, Wu Z, Wu Y, Yang R, Liu Y . Ultra-Long GnRH Agonist Protocol During IVF/ICSI Improves Pregnancy Outcomes in Women With Adenomyosis: A Retrospective Cohort Study. Front Endocrinol (Lausanne). 2021; 12:609771. PMC: 8202082. DOI: 10.3389/fendo.2021.609771. View

Fiszbajn G, Lipowicz R, Elberger L, Grabia A, Papier S, Brugo Olmedo S . Conservative management versus aspiration of functional ovarian cysts before ovarian stimulation for assisted reproduction. J Assist Reprod Genet. 2000; 17(5):260-3. PMC: 3455200. DOI: 10.1023/a:1009406315729. View

Wang F, Dai W, Yang X, Guo Y, Sun Y . Analyses of optimal body mass index for infertile patients with either polycystic or non-polycystic ovary syndrome during assisted reproductive treatment in China. Sci Rep. 2016; 6:34538. PMC: 5043278. DOI: 10.1038/srep34538. View

Owj M, Ashrafi M, Baghestani A . Ovarian cyst formation and in vitro fertilization outcome. Int J Gynaecol Obstet. 2004; 87(3):258-9. DOI: 10.1016/j.ijgo.2004.08.004. View

Biljan M, Lapensee L, Mahutte N, Bissonnette F, Hemmings R, Tan S . Effects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment. Fertil Steril. 2000; 74(5):941-5. DOI: 10.1016/s0015-0282(00)01555-7. View

Broekmans F, Bernardus R, Berkhout G, Schoemaker J . Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR. Gynecol Endocrinol. 1992; 6(3):153-61. DOI: 10.3109/09513599209015549. View

Tarlatzis B, Bili H, Bontis J, Lagos S, Vatev I, Mantalenakis S . Follicle cyst formation after administration of different gonadotrophin-releasing hormone analogues for assisted reproduction. Hum Reprod. 1994; 9(11):1983-6. DOI: 10.1093/oxfordjournals.humrep.a138378. View

10.

Nett T, Turzillo A, Baratta M, Rispoli L . Pituitary effects of steroid hormones on secretion of follicle-stimulating hormone and luteinizing hormone. Domest Anim Endocrinol. 2002; 23(1-2):33-42. DOI: 10.1016/s0739-7240(02)00143-1. View

11.

Dal Prato L, Borini A, Cattoli M, Bonu M, Sciajno R, Flamigni C . Endometrial preparation for frozen-thawed embryo transfer with or without pretreatment with gonadotropin-releasing hormone agonist. Fertil Steril. 2002; 77(5):956-60. DOI: 10.1016/s0015-0282(02)02960-6. View

12.

Qublan H, Amarin Z, Tahat Y, Smadi A, Kilani M . Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact. Hum Reprod. 2005; 21(3):640-4. DOI: 10.1093/humrep/dei371. View

13.

Sharma S, Bathwal S, Agarwal N, Chattopadhyay R, Saha I, Chakravarty B . Does presence of adenomyosis affect reproductive outcome in IVF cycles? A retrospective analysis of 973 patients. Reprod Biomed Online. 2018; 38(1):13-21. DOI: 10.1016/j.rbmo.2018.09.014. View

14.

Tsai H, Wang P, Lin L, Chen S, Tsui K . Using gonadotropin-releasing hormone agonist before frozen embryo transfer may improve ongoing pregnancy rates in hyperandrogenic polycystic ovary syndrome women. Gynecol Endocrinol. 2017; 33(9):686-689. DOI: 10.1080/09513590.2017.1307961. View

15.

Yuan C, Liu X, Mao Y, Diao F, Cui Y, Liu J . Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess: a prospective study. J Biomed Res. 2016; 30(3):197-202. PMC: 4885167. DOI: 10.7555/JBR.30.20140111. View

16.

McDonnell R, Marjoribanks J, Hart R . Ovarian cyst aspiration prior to in vitro fertilization treatment for subfertility. Cochrane Database Syst Rev. 2014; (12):CD005999. PMC: 6483607. DOI: 10.1002/14651858.CD005999.pub2. View

17.

Liu K, Hartman M, Hartman A, Luo Z, Mahutte N . The impact of a thin endometrial lining on fresh and frozen-thaw IVF outcomes: an analysis of over 40 000 embryo transfers. Hum Reprod. 2018; 33(10):1883-1888. PMC: 6145412. DOI: 10.1093/humrep/dey281. View

18.

Feldberg D, Ashkenazi J, Yeshaya A, Goldman G, Dicker D, Goldman J . Ovarian cyst formation: a complication of gonadotropin-releasing hormone agonist therapy. Fertil Steril. 1989; 51(1):42-5. DOI: 10.1016/s0015-0282(16)60425-9. View

19.

Ghobara T, Gelbaya T, Ayeleke R . Cycle regimens for frozen-thawed embryo transfer. Cochrane Database Syst Rev. 2017; 7:CD003414. PMC: 6483463. DOI: 10.1002/14651858.CD003414.pub3. View

20.

Sallam H, Garcia-Velasco J, Dias S, Arici A . Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev. 2006; (1):CD004635. PMC: 8195082. DOI: 10.1002/14651858.CD004635.pub2. View